Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic
Recently published research findings suggest that we may be able to prevent Cytokine Release Syndrome (CRS) through the oral administration of an FDA-approved drug. CAR-T therapy is a promising new approach to cancer treatment. However, a devastating side effect of CAR-T cell infusion is CRS. The patient’s infused activated T cells release interferon gamma (IFN-γ)
Chimeric antigen receptor T cell (CAR T) therapies have proved remarkably effective against leukemia and lymphoma, but for these therapies to target other types of cancer, there are still hurdles to overcome. Brain cancer is particularly challenging for immunotherapies due to the blood-brain barrier. This semi-permeable barrier tightly regulates the homeostasis of the central nervous
As a scorching summer draws to a close and conference season begins, Akron will be participating at many upcoming events to further advocate for the use of higher quality ancillary materials in regenerative medicine processes. Our focus of providing affordable cGMP reagents throughout the development stages for these unique therapeutics serves to better ensure reproducibility
Chimeric antigen receptors (CARs) significantly enhance the anti-tumor activity of immune effector cells. Current CAR-based immunotherapies leverage engineered versions of a patient’s own T-cells to target and kill cancer cells. Recently, a study led by researchers at University of California San Diego School of Medicine and University of Minnesota demonstrated that similarly modified CAR constructs
T cells expressing chimeric antigen receptors (CAR T) are particularly promising for the treatment of refractory cancers. While Kymriah and Yescarta are FDA-approved for B-cell malignancies, safety and efficacy concerns remain across the cell therapy industry. Severe cytokine release syndrome triggered by T cell infusion is one of the urgent CAR T related downsides that needs
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have terrible prognoses and novel cell therapies provide a glimmer of hope. While the CAR T therapy known as Kymriah led to complete remission in over 90% of patients with advanced acute lymphoblastic leukemia (ALL), only 26% of CLL patients responded to it in clinical trials.
Diffuse intrinsic pontine glioma (DIPG) with mutated histone H3 K27M is an extremely aggressive, universally fatal pediatric brain cancer. DIPG affects a few hundred children across the country each year and typically exhibits rapid clinical onset and progression with 90% mortality rate within 18 months of presentation. There is no cure and no effective treatment.
On the heels of August’s approval of Novartis’ CAR-T therapy Kymriah, FDA has this week announced a second approval of another CAR-T therapy. This time, it is for Kite Pharma’s Yescarta. While this is the second CAR-T therapy to be approved, it is the first for certain types of non-Hodgkin lymphoma (NHL). Yescarta is developed
About two months and two weeks after the FDA’s advisory committe recommended for approval Novartis’ CAR-T therapy for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL), the FDA followed up with an official approval. Tisagenlecleucel – or, as the therapy is commonly known, Kymriah – will head